Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.43 USD
+0.08 (5.93%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Enlivex Therapeutics Ltd.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ENLV 1.43 +0.08(5.93%)
Will ENLV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENLV
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for October 23rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
Other News for ENLV
Enlivex Therapeutics (ENLV) Receives Continued Buy Rating with $13 Price Target | ENLV Stock News
Enlivex Therapeutics (ENLV) Completes Key Trial Stage for Allocetra
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data | ...
Enlivex reaffirms August 18 as target date for Phase II data announcement
Enlivex Therapeutics (ENLV) Receives Continued 'Buy' Rating from Analyst | ENLV Stock News